Discussing REFLECT Phase 3 Study Utilizing Lenvatinib & Recent Approval Of Cabozantinib

Discussing REFLECT Phase 3 Study Utilizing Lenvatinib & Recent Approval Of Cabozantinib

obr

11 months
88 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses REFLECT Phase 3 Study Utilizing Lenvatinib & Recent Approval Of Cabozantinib. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com
Up Next Autoplay
Phase 3 TAGS Study Evaluating LONSURF
Phase 3 TAGS Study Evaluating LONSURF
Category: Gastrointestinal Cancer
17 Views
Cancer-News 3 weeks
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Category: Gastrointestinal Cancer
11 Views
Massachusetts General Hospital 2 months
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Category: Gastrointestinal Cancer
18 Views
Massachusetts General Hospital 2 months
Intestinal Tumor Commonly Asked Questions
Intestinal Tumor Commonly Asked Questions
Category: Gastrointestinal Cancer
20 Views
Massachusetts General Hospital 2 months
Drug Resistance Found As Intestinal Tumor
Drug Resistance Found As Intestinal Tumor
Category: Gastrointestinal Cancer
21 Views
Massachusetts General Hospital 2 months
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Category: Gastrointestinal Cancer
182 Views
obr 6 months
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
219 Views
Annual-Meeting 7 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
27 Views
Annual-Meeting 7 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
127 Views
Annual-Meeting 7 months
Caring For Every Patient And Learning From Every Patient
Caring For Every Patient And Learning From Every Patient
Category: Gastrointestinal Cancer
160 Views
Annual-Meeting 7 months